In mCRPC, more patients preferred cabazitaxel compared with docetaxel (43% vs 27%); 30% of patients had no preference.

Final results from the CABADOC trial reveal that for 195 men who were randomized to receive either docetaxel followed by cabazataxel or vice versa, as treatment for their mCRPC, more men preferred cabazitaxel based on QoL issues such as fatigue, hair loss and/or pain.  There was no difference in efficacy.

For the full ASCO abstract, click here: http://abstracts.asco.org/239/AbstView_239_261513.html